Category: Biolase Technology Inc.Syndicate content

Second Sight eyes $10M funding round | Wall Street Beat

July 25, 2013 by Brad Perriello

Second Sight Medical registers for a $10 million funding round to back its Argus II 'bionic eye' retinal implant.

MassDevice.com Wall Street Beat

Second Sight Medical is hoping to raise $10.5 million, according to a regulatory filing, as it brings its "bionic eye" Argus II retinal implant to the U.S. market.

The device, comprised of an eyeglass-mounted camera and an electrical stimulator implanted in the eye, works by converting video images captured by a miniature camera housed in the patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Mindray tag-teams CEO position | Personnel Moves

June 14, 2013 by Sony Salzman

Two heads are better than 1 at Mindray Medical, which appointed chief strategic officer Cheng Minghe as co-CEO alongside chief Li Xiting.

fired/hired

Mindray Medical (NYSE:MR) chief Li Xiting will share the corner office, so to speak, with new co-CEO Cheng Minghe, who takes the new title in addition to continuing as the company's chief strategic officer.

Cheng is one of the founders of the Shenzhen, China-based company, and has worked in various roles since 1991.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biolase quashes rumors of CEO departure | Personnel Moves

June 10, 2013 by Sony Salzman

Biolase CEO Federico Pignatelli, who made waves with his commitment to a $1 salary, denies rumors that he is stepping down.

fired/hired

Biolase (NSDQ:BLTI) issued a message to concerned investors, quashing rumors of CEO Federico Pignatelli's imminent departure and asserting his continued leadership of the dental laser company.

Biolase gets FDA nod for new tissue laser

May 13, 2013 by Sony Salzman

The FDA clears Biolase's WaterLase iPlus tissue laser in the U.S.

Biolase

Biolase (NSDQ:BIOL) won 510(k) clearance from the FDA for its WaterLase iPlus, a laser used for soft-tissue orthopedic procedures.

The clearance opens up a $2.6 billion market opportunity for the WaterLase device, according to a company statement.

Biolase's FDA win includes more than 80 indications for soft tissue laser

April 11, 2013 by Arezu Sarvestani

California medical device maker Biolase won FDA clearance to market its EPIC 10S soft tissue diode laser for more than 80 indications.

Biolase logo

Dental devices maker Biolase (NSDQ:BIOL) touted FDA clearance for its EPIC 10S soft tissue diode laser, which the company can now market for more than 80 indications spanning 19 medical markets.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Ad-Tech brain implant recall gets FDA's highest-risk status | MassDevice.com On Call

March 8, 2013 by Arezu Sarvestani

The FDA placed Class I risk status on Ad-Tech Medical Instrument Corp.'s recall of its Macro Micro Subdural Electrodes over concerns that the brain implants may cause injury to the brain.

MassDevice On Call

MASSDEVICE ON CALL — Federal healthcare regulators gave Ad-Tech Medical Instrument Corp.'s wide-reaching brain implant recall Class I status, the highest-risk category for medical device recalls.

Late last year the Wisconsin-based medical device maker recalled its Macro Micro Subdural Electrodes over concerns that the implanted devices could cause damage to the brain.

Ex-KCI CEO Burzik dives into venture capital | Personnel Moves

February 27, 2013 by Sony Salzman

Catherine Burzik, former CEO of Kinetic Concepts, is teaming up with Incyte Ventures to raise $50 million for biomed and biotech start-ups in San Antonio, Texas.

fired/hired

 Ex-Kinetic Concepts CEO Burzik turns her sights to startups

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp